Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1

7(87.5%)

N/A

1(12.5%)

8Total

Early Phase 1(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07561437Early Phase 1Recruiting

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Role: lead

NCT06097962Early Phase 1Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

Role: lead

NCT07166263Early Phase 1Not Yet Recruiting

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Role: lead

NCT07083349Not ApplicableNot Yet Recruiting

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Role: lead

NCT06541405Early Phase 1Recruiting

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT06541444Early Phase 1Recruiting

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT06117878Early Phase 1Unknown

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Role: lead

NCT06098898Early Phase 1Unknown

Safety and Efficacy of NK510 to Treat Gastric Cancer

Role: lead

All 8 trials loaded